Reimbursement Review Reports


( Last Updated : October 1, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Afinitor Everolimus Subependymal giant cell astrocytoma associated with tuberous sclerosis complex Do not list Complete
Aimovig erenumab Migraine Reimburse with clinical criteria and/or conditions Complete
Ajovy fremanezumab migraine Reimburse with clinical criteria and/or conditions Complete
Akynzeo netupitant / palonosetron Nausea and vomiting (chemotherapy induced) prevention Reimburse with clinical criteria and/or conditions Complete
Albrioza sodium phenylbutyrate and ursodoxicoltaurine Amyotrophic lateral sclerosis (ALS) Reimburse with clinical criteria and/or conditions Active
Aldurazyme Laronidase Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie Do not list Complete
Alecensaro Alectinib Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Alecensaro Alectinib Non-Small Cell Lung Cancer Do not reimburse Complete
Alecensaro Alectinib Locally advanced or metastatic ALK+ NSCLC (first line) Reimburse with clinical criteria and/or conditions Complete
Alimta Pemetrexed Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete